IGF1-LR3, thanks to its long half-life, is highly effective in counteracting myostatin and appears to work by activating a muscle protein called MyoD [1], [2]
From chairside chats to expert intel, stay ahead of the curve
Tirzepatide users lost about 20% of their body weight, while semaglutide users averaged around 14%
Patients taking GLP-1 receptor agonists in combination with insulin or sulfonylureas face increased hypoglycemia risk and should be counseled to check blood glucose when experiencing these symptoms
97 have shown that 1040% CR over 3 months in C57BL/6 mice (corresponding to approximately a tenth of their lifespan) decreases blood glucose, insulin and IGF-1 concentrations, the latter showing the greatest dependence upon the severity of CR
As you can imagine, when you feel fuller longer, and you dont have as much appetite, lots of people are losing really impressive amounts of weight